Fibroadenoma risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 16: | Line 16: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Obesity'''|| style="padding: 5px 5px; background: #F5F5F5;" |An increase in BMI is correlated with an increased risk of fibroadenoma development. | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''[[Obesity]]'''|| style="padding: 5px 5px; background: #F5F5F5;" |An increase in [[BMI]] is correlated with an increased risk of fibroadenoma development. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Estrogen replacement therapy'''|| style="padding: 5px 5px; background: #F5F5F5;" |Estrogen replacement therapy is correlated with an increased risk of fibroadenoma development. | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''[[Estrogen]] replacement therapy'''|| style="padding: 5px 5px; background: #F5F5F5;" |[[Estrogen replacement therapy]] is correlated with an increased risk of fibroadenoma development. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Pregnancy'''|| style="padding: 5px 5px; background: #F5F5F5;" |Nulliparous women are associated with an increased risk of fibroadenoma development. Whereas multiparous women are associated with a lower risk of fibroadenoma development. | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''[[Pregnancy]]'''|| style="padding: 5px 5px; background: #F5F5F5;" |[[Pregnancy|Nulliparous]] women are associated with an increased risk of fibroadenoma development. Whereas [[Pregnancy|multiparous]] women are associated with a lower risk of fibroadenoma development. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Contraception'''|| style="padding: 5px 5px; background: #F5F5F5;" | The use of oral contraceptive | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''[[Contraception]]'''|| style="padding: 5px 5px; background: #F5F5F5;" | The use of [[oral contraceptive pill]]s is associated with a lower risk of fibroadenoma development as compared to other contraceptive methods. | ||
|- | |- | ||
Revision as of 13:05, 2 February 2016
|
Fibroadenoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fibroadenoma risk factors On the Web |
|
American Roentgen Ray Society Images of Fibroadenoma risk factors |
|
Risk calculators and risk factors for Fibroadenoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
Common risk factors in the development of fibroadenoma are obesity, eostrogen replacement therapy, and nulliparity.[1][2]
Risk Factors
| Risk Factor | Description |
|---|---|
| Obesity | An increase in BMI is correlated with an increased risk of fibroadenoma development. |
| Estrogen replacement therapy | Estrogen replacement therapy is correlated with an increased risk of fibroadenoma development. |
| Pregnancy | Nulliparous women are associated with an increased risk of fibroadenoma development. Whereas multiparous women are associated with a lower risk of fibroadenoma development. |
| Contraception | The use of oral contraceptive pills is associated with a lower risk of fibroadenoma development as compared to other contraceptive methods. |
| Socioeconomic status | A higher socioeconomic status is correlated with an increased risk of fibroadenoma development. |
References
- ↑ 1.0 1.1 Greenberg R, Skornick Y, Kaplan O (1998). "Management of breast fibroadenomas". J Gen Intern Med. 13 (9): 640–5. PMC 1497021. PMID 9754521.
- ↑ 2.0 2.1 Fibroadenoma. Wikipedia (2015) https://en.wikipedia.org/wiki/Fibroadenoma Accessed on January, 29 2016